Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial

Generalized Additive Models: An Introduction with R

Wood, S. N. (2017) · doi:10.1201/9781315370279 · Cited by 13,852

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897

Sensitivity analysis in observational research: Introducing the E-value

VanderWeele, T. J., & Ding, P. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2607 · Cited by 6,350

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2180-5 · Cited by 5,983

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A., & Davenport, M. P. (2021) · Nature Medicine · doi:10.1038/s41591-021-01377-8 · Cited by 3,742

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237

Cell entry mechanisms of SARS-CoV-2

Shang, J., Wan, Y., Luo, C., Ye, G., Geng, Q., Auerbach, A., & Li, F. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2003138117 · Cited by 3,142

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

Letko, M., Marzi, A., & Munster, V. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0688-y · Cited by 3,109

Assessment of safety and intranasal neutralizing antibodies of HPMC-based human anti-SARS-CoV-2 IgG1 nasal spray in healthy volunteers

Imsuwansri, T., Jongthitinon, T., Pojdoung, N., Meesiripan, N., Sakarin, S., Boonkrai, C., Wongtangprasert, T., Phakham, T., Audomsun, T., Attakitbancha, C., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-42539-7 · Cited by 15

Stochastic Interventional Vaccine Efficacy and Principal Surrogate Analyses of Antibody Markers as Correlates of Protection against Symptomatic COVID-19 in the COVE mRNA-1273 Trial

Huang, Y., Hejazi, N. S., Blette, B. S., Carpp, L. N., Benkeser, D. C., Montefiori, D. C., McDermott, A. B., Fong, Y., Janes, H., Deng, W., et al. (2023) · Viruses · doi:10.3390/v15102029 · Cited by 15

Anti-SARS-CoV-2 Antibody Testing: Role and Indications

Mink, S., & Fraunberger, P. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12247575 · Cited by 16

Predictors of Breakthrough SARS-CoV-2 Infection after Vaccination

Walmsley, S. L., Nabipoor, M., Lovblom, L. E., Ravindran, R., Colwill, K., McGeer, A., Dayam, R. M., Manase, D., Gingras, A., & on behalf of the STOPCoV Team (2023) · Vaccines · doi:10.3390/vaccines12010036 · Cited by 15

Silent battles: immune responses in asymptomatic SARS-CoV-2 infection

Bert, N. L., & Samandari, T. (2024) · Cellular and Molecular Immunology · doi:10.1038/s41423-024-01127-z · Cited by 16

Contralateral second dose improves antibody responses to a 2-dose mRNA vaccination regimen

Fazli, S., Thomas, A., Estrada, A. E., Ross, H. A. P., Lee, D. X., Kazmierczak, S. C., Slifka, M. K., Montefiori, D. C., Messer, W. B., & Curlin, M. E. (2024) · Journal of Clinical Investigation · doi:10.1172/jci176411 · Cited by 16

Integrating clinical research into electronic health record workflows to support a learning health system

Goldhaber, N. H., Jacobs, M. B., Laurent, L. C., Knight, R. D., Zhu, W., Pham, D., Tran, A., Patel, S. P., Hogarth, M. A., & Longhurst, C. (2024) · JAMIA Open · doi:10.1093/jamiaopen/ooae023 · Cited by 15

Antibody‐mediated control mechanisms of viral infections

Mackin, S., Sariol, A., & Diamond, M. (2024) · Immunological Reviews · doi:10.1111/imr.13383 · Cited by 15

Early antiviral CD4+ and CD8+ T cells are associated with upper airway clearance of SARS-CoV-2

Ramirez, S. I., Lopez, P. G., Faraji, F., Parikh, U. M., Heaps, A., Ritz, J., Moser, C., Eron, J. J., Wohl, D. A., Currier, J. S., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.186078 · Cited by 23

Safety and Immunogenicity of SARS-CoV-2 Spike Receptor-Binding Domain and N-Terminal Domain mRNA Vaccine

Chalkias, S., Pragalos, A., Akinsola, A., Berman, G., Ampajwala, M., Meyer, J. W., Schoch, L., Zhou, W., Paila, Y. D., Deng, W., et al. (2025) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaf022 · Cited by 15

Quantitative serology for SARS-CoV-2 using self-collected saliva and finger-stick blood

Campbell, C., Padmanabhan, N., Romero, D., Joe, J., Gebremeskel, M., Manjula, N., Wohlstadter, N., Wohlstadter, R., Goodwin, P., Quintero, L., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-10484-6 · Cited by 14

mRNA vaccine boosting enhances antibody responses against SARS-CoV-2 Omicron variant in individuals with antibody deficiency syndromes

Zimmerman, O., Doss, A. M. A., Kapłonek, P., Liang, C.-Y., VanBlargan, L. A., Chen, R. E., Monroy, J. M., Wedner, H. J., Kulczycki, A., Mantia, T. L., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100653 · Cited by 15

SARS-CoV-2 Convalescent Sera Binding and Neutralizing Antibody Concentrations Compared with COVID-19 Vaccine Efficacy Estimates against Symptomatic Infection

Schuh, A. J., Satheshkumar, P. S., Dietz, S., Bull–Otterson, L., Charles, M. D., Edens, C., Jones, J. M., Bajema, K. L., Clarke, K. E. N., McDonald, L. C., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.01247-22 · Cited by 15

Kinetics of anti-SARS-CoV-2 antibody titer in healthy adults up to 6 months after BNT162b2 vaccination measured by two immunoassays: A prospective cohort study in Japan

Matsuura, T., Fukushima, W., Nakagama, Y., Kido, Y., Kase, T., Kondo, K., Kaku, N., Matsumoto, K., Suita, A., Komiya, E., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.08.018 · Cited by 14

Predictors of impaired antibody response after SARS‐CoV ‐2 mRNA vaccination in hematopoietic cell transplant recipients: A Japanese multicenter observational study

Mori, Y., Uchida, N., Harada, T., Katayama, Y., Wake, A., Iwasaki, H., Eto, T., Morishige, S., Fujisaki, T., Ito, Y., et al. (2022) · American Journal of Hematology · doi:10.1002/ajh.26769 · Cited by 13

Humoral immunity for durable control of SARS-CoV-2 and its variants

Kotaki, R., Moriyama, S., & Takahashi, Y. (2023) · Inflammation and Regeneration · doi:10.1186/s41232-023-00255-9 · Cited by 15

Acute SARS-CoV-2 infection

Sherman, A. C., Gray, G., Cao, B., To, K. K., Rouphael, N., Restrepo, A. M. H., Gordon, A. C., & Baden, L. R. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00662-x · Cited by 19

Distinct sensitivities to SARS-CoV-2 variants in vaccinated humans and mice

Walls, A. C., VanBlargan, L. A., Wu, K., Choi, A., Navarro, M. J., Lee, D. W., Avena, L. E., Berrueta, D. M., Pham, M. N., Elbashir, S. M., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111299 · Cited by 13

Recent Developments in the Understanding of Immunity, Pathogenesis and Management of COVID-19

Yegiazaryan, A., Abnousian, A., Alexander, L. J., Badaoui, A., Flaig, B., Sheren, N., Aghazarian, A., Alsaigh, D., Amin, A., Mundra, A., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169297 · Cited by 14

Clinical usefulness of testing for severe acute respiratory syndrome coronavirus 2 antibodies

Alexopoulos, H., Trougakos, I., Dimopoulos, M., & Terpos, E. (2022) · European journal of internal medicine · doi:10.1016/j.ejim.2022.11.009 · Cited by 14

AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants

Giesen, N., Busch, E., Schalk, E., Beutel, G., Rüthrich, M. M., Hentrich, M., Hertenstein, B., Hirsch, H. H., Karthaus, M., Khodamoradi, Y., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.11.030 · Cited by 14

Ad26.COV2.S and SARS-CoV-2 spike protein ferritin nanoparticle vaccine protect against SARS-CoV-2 Omicron BA.5 challenge in macaques

Yu, J., Thomas, P. V., Sciacca, M., Wu, C., Liu, J., He, X., Miller, J. J., Hachmann, N. P., Surve, N., McMahan, K., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101018 · Cited by 14

From Detection to Protection: Antibodies and Their Crucial Role in Diagnosing and Combatting SARS-CoV-2

Kumar, A., Tripathi, P., Kumar, P., Shekhar, R., & Pathak, R. (2024) · Vaccines · doi:10.3390/vaccines12050459 · Cited by 17

Omicron COVID-19 immune correlates analysis of a third dose of mRNA-1273 in the COVE trial

Zhang, B., Fong, Y., Fintzi, J., Chu, E., Janes, H., Kenny, A., Carone, M., Benkeser, D. C., van der Laan, L. W. P., Deng, W., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52348-9 · Cited by 14

Phase II study on the safety and immunogenicity of single-dose intramuscular or intranasal administration of the AVX/COVID-12 “Patria” recombinant Newcastle disease virus vaccine as a heterologous booster against COVID-19 in Mexico

López-Macías, C. I. R., Torres, M., Armenta-Copca, B., Wacher, N. H., Castro-Castrezana, L., Colli-Domínguez, A. A., Rivera-Hernández, T., Torres-Flores, A., Damián-Hernández, M., Ramírez-Martínez, L. A., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.126511 · Cited by 18

Comparative Immunogenicity of COVID-19 Vaccines in a Population-Based Cohort Study with SARS-CoV-2-Infected and Uninfected Participants

Peterhoff, D., Einhauser, S., Beileke, S., Niller, H.-H., Günther, F., Schachtner, M., Asbach, B., Steininger, P. A., Tenbusch, M., Peter, A. S., et al. (2022) · Vaccines · doi:10.3390/vaccines10020324 · Cited by 14

Antibody and Memory B-Cell Immunity in a Heterogeneously SARS-CoV-2-Infected and -Vaccinated Population

Bednarski, E., Estrada, P. M. D. R., DaSilva, J., Boukadida, C., Zhang, F., Luna-Villalobos, Y. A., Rodríguez-Rangel, X., Pitén-Isidro, E., Luna-García, E., Díaz-Rivera, D., et al. (2022) · mBio · doi:10.1128/mbio.00840-22 · Cited by 15

Immunogenicity of BNT162b2 COVID-19 vaccine in New Zealand adults

Priddy, F. H., Williams, M., Carson, S., Lavender, B., Mathieson, J., Frampton, C., Moreland, N. J., McGregor, R., Williams, G., Brewerton, M., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.07.009 · Cited by 16

Direct capture of neutralized RBD enables rapid point-of-care assessment of SARS-CoV-2 neutralizing antibody titer

Connelly, G. G., Kirkland, O. O., Bohannon, S., Lim, D., Wilson, R. M., Richards, E. J., Tay, D. M. Y., Jee, H., Hellinger, R. D., Hoang, N. K., et al. (2022) · Cell Reports Methods · doi:10.1016/j.crmeth.2022.100273 · Cited by 16

Safety and Immunogenicity of Betuvax-CoV-2, an RBD-Fc-Based SARS-CoV-2 Recombinant Vaccine: Preliminary Results of the First-in-Human, Randomized, Double-Blind, Placebo-Controlled Phase I/II Clinical Trial

Kudriavtsev, A. V., Vakhrusheva, A., Kryuchkov, N. A., Frolova, M. E., Blagodatskikh, K. А., Ivanishin, T. V., Djonovic, M., Romanovskaya-Romanko, E., Kovalenko, A. N., Lioznov, D. A., et al. (2023) · Vaccines · doi:10.3390/vaccines11020326 · Cited by 14

Second monovalent SARS-CoV-2 mRNA booster restores Omicron-specific neutralizing activity in both nursing home residents and health care workers

Nugent, C., Abul, Y., White, E. M., Shehadeh, F., Kaczynski, M., Felix, L. O., Ganesan, N., Oyebanji, O. A., Vishnepolskiy, I., Didion, E. M., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.04.034 · Cited by 15

Safety and immunogenicity of a SARS-CoV-2 Gamma variant RBD-based protein adjuvanted vaccine used as booster in healthy adults

Pasquevich, K. A., Coria, L. M., Ceballos, A., Mazzitelli, B., Rodriguez, J. M., Demaría, A., Castro, C. P., Bruno, L. A., Saposnik, L. M., Salvatori, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40272-3 · Cited by 18

Safety and Immunogenicity of a 100 μg mRNA-1273 Vaccine Booster for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)Preprint

Chalkias, S., Schwartz, H., Nestorova, B., Feng, J., Chang, Y., Zhou, H., Dutko, F. J., Edwards, D. K., Montefiori, D. C., Pajón, R., et al. (2022) · medRxiv · doi:10.1101/2022.03.04.22271830 · Cited by 13

Increasing polycation hydrophobicity in mRNA polyplex vaccines enhances the efficacy of humoral and cellular immunity induction

Qiao, N., Hori, M., Naito, M., Chang, H., Ogura, S., Suzuki, M., Kimura, T., Fukushima, S., Kim, H. J., Uchida, S., et al. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123515 · Cited by 14

Evaluation of the Humoral Immune Response of a Heterologous Vaccination between BBIBP-CorV and BNT162b2 with a Temporal Separation of 7 Months, in Peruvian Healthcare Workers with and without a History of SARS-CoV-2 Infection

Hueda-Zavaleta, M., de la Torre, J. C. G., Cáceres-DelAguila, J. A., Muro-Rojo, C., Cruz-Escurra, N. D. L., Siles, D. A., Minchón-Vizconde, D., Corzo, C. A. C., Bardales-Silva, F., Benites-Zapata, V. A., et al. (2022) · Vaccines · doi:10.3390/vaccines10040502 · Cited by 14

Approaches to demonstrating the effectiveness of filovirus vaccines: Lessons from Ebola and COVID-19

Gruber, M. F., Rubin, S. A., & Krause, P. R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1109486 · Cited by 13

SARS-CoV-2 live virus neutralization after four COVID-19 vaccine doses in people with HIV receiving suppressive antiretroviral therapy

Cheung, P. K., Lapointe, H. R., Sang, Y., Ennis, S., Mwimanzi, F. M., Speckmaier, S., Barad, E., Dong, W. W. Y., Liang, R., Simons, J. E., et al. (2023) · AIDS · doi:10.1097/qad.0000000000003519 · Cited by 13

Dynamic Evolution of Humoral and T-Cell Specific Immune Response to COVID-19 mRNA Vaccine in Patients with Multiple Sclerosis Followed until the Booster Dose

Ruggieri, S., Aiello, A., Tortorella, C., Navarra, A., Vanini, V., Meschi, S., Lapa, D., Haggiag, S., Prosperini, L., Cuzzi, G., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108525 · Cited by 13

Integrated antibody and cellular immunity monitoring are required for assessment of the long term protection that will be essential for effective next generation vaccine development

Paramithiotis, E., Varaklis, C., Pillet, S., Shafiani, S., Lancelotta, M. P., Steinhubl, S. R., Sugden, S., Clutter, M., Montamat‐Sicotte, D., Chermak, T., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1166059 · Cited by 13

Safety, immunogenicity, and preliminary efficacy of a randomized clinical trial of omicron XBB.1.5-containing bivalent mRNA vaccine

Yu, X., Yang, W. J., Li, W., Wan, N., Yan, G., Zhou, Z., Zhu, X. M., Su, W., Li, Y., Xing, C., et al. (2024) · hLife · doi:10.1016/j.hlife.2024.01.005 · Cited by 13

Prognostic value of anti-SARS-CoV-2 antibodies: a systematic review

Mink, S., Reimann, P., & Fraunberger, P. (2024) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2023-1487 · Cited by 14

Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features

Magaret, C. A., Li, L., deCamp, A. C., Rolland, M., Juraska, M., Williamson, B. D., Ludwig, J., Molitor, C., Benkeser, D. C., Luedtke, A. R., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46536-w · Cited by 14

XBB .1.5‐Adapted COVID ‐19 mRNA Vaccines but Not Infections With Previous Omicron Variants Boost Neutralisation Against the SARS ‐ CoV ‐2 JN .1 Variant in Patients With Inflammatory Bowel Disease

Woelfel, S., Dütschler, J., Junker, D., König, M., Graf, N., Krieger, C., Truniger, S., Oikonomou, V., Leinenkugel, G., Koller, S., et al. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18349 · Cited by 15

Neutralizing Antibody Response to Pseudotype Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Differs Between mRNA-1273 and BNT162b2 Coronavirus Disease 2019 (COVID-19) Vaccines and by History of SARS-CoV-2 Infection

Tyner, H. L., Burgess, J. L., Grant, L., Gaglani, M., Kuntz, J. L., Naleway, A. L., Thornburg, N. J., Caban-Martinez, A. J., Yoon, S. K., Herring, M. K., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab1038 · Cited by 13

Review of Ribosome Interactions with SARS-CoV-2 and COVID-19 mRNA Vaccine

Wei, J., & Hui, A. (2022) · Life · doi:10.3390/life12010057 · Cited by 13

Strong Decay of SARS-CoV-2 Spike Antibodies after 2 BNT162b2 Vaccine Doses and High Antibody Response to a Third Dose in Nursing Home Residents

Blain, H., Tuaillon, É., Gamon, L., Pisoni, A., Miot, S., & Picot, M. (2022) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2022.02.006 · Cited by 13

Production and Quality Assurance of Human Polyclonal Hyperimmune Immunoglobulins Against SARS-CoV-2

Burnouf, T., Gathof, B. S., Bloch, E. M., Bazin, R., Angelis, V. D., Patidar, G. K., Rastvorceva, R. M. G., Oreh, A. C., Goel, R., Rahimi‐Levene, N., et al. (2022) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2022.06.001 · Cited by 13

Vaccine subtype and dose interval determine immunogenicity of primary series COVID-19 vaccines in older people

Parry, H., Bruton, R. K., Ayodele, R., Sylla, P., McIlroy, G., Logan, N. A., Scott, S., Nicol, S., Verma, K., Stephens, C., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100739 · Cited by 12

SARS‐CoV‐2 evolves to reduce but not abolish neutralizing action

Zhang, Y., Ndzouboukou, J. B., Lin, X., Hou, H., Wang, F., Yuan, L., Gan, M., Yao, Z., Fu, H., Cao, J., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28207 · Cited by 12

The duration and breadth of antibody responses to 3-dose of inactivated COVID-19 vaccinations in healthy blood donors: An observational study

Ou, S.-H., Huang, Z., Lan, M., Ye, J., Chen, J., Guo, H., Xiao, J., Zhuang, S., Wu, J., Yang, C., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1027924 · Cited by 13

BNT162b2 induces robust cross-variant SARS-CoV-2 immunity in children

Bartsch, Y. C., Chen, J. W., Kang, J., Burns, M. D., Denis, K. S., Sheehan, M. L., Davis, J. P., Edlow, A. G., Balazs, A. B., Yonker, L. M., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00575-w · Cited by 14

Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vaccine) in adults in a phase 2/3, observer-blind, randomised, controlled study

Kulkarni, P. S., Kadam, A., Godbole, S., Bhatt, V. R., Raut, A. V., Kohli, S., Tripathi, S. K., Kulkarni, P., Ludam, R., Prabhu, M., et al. (2023) · The Lancet Regional Health - Southeast Asia · doi:10.1016/j.lansea.2022.100139 · Cited by 13

Estimated COVID-19 vaccine effectiveness against seroconversion from SARS-CoV-2 Infection, March–October, 2021

Plumb, I. D., Fette, L. M., Tjaden, A. H., Feldstein, L. R., Saydah, S., Ahmed, A., Link‐Gelles, R., Wierzba, T. F., Berry, A. A., Friedman-Klabanoff, D. J., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.03.006 · Cited by 12

Evaluation of antibody kinetics and durability in healthy individuals vaccinated with inactivated COVID-19 vaccine (CoronaVac): A cross-sectional and cohort study in Zhejiang, China

Zhang, H., Hua, Q., Xu, N., Zhang, X., Chen, B., Xi-jun, M., Hu, J., Chen, Z., Yu, P., Lei, H., et al. (2023) · eLife · doi:10.7554/elife.84056 · Cited by 17

Ability of SpikoGen ®, an Advax‐CpG adjuvanted recombinant spike protein vaccine, to induce cross‐neutralising antibodies against SARS‐CoV ‐2 variants

Honda‐Okubo, Y., Antipov, A., André, G. O., Barati, S., Kafi, H., & Petrovsky, N. (2023) · Immunology · doi:10.1111/imm.13661 · Cited by 13

GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial

Capone, S., Fusco, F. M., Milleri, S., Borrè, S., Carbonara, S., Caputo, S. L., Leone, S., Gori, G., Maggi, P., Cascio, A., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101084 · Cited by 13

A potential silver lining of delaying the second dose

Martinez, D. R., & Ooi, E. E. (2022) · Nature Immunology · doi:10.1038/s41590-022-01143-z · Cited by 12

Severe Acute Respiratory Syndrome Coronavirus 2 Hyperimmune Intravenous Human Immunoglobulins Neutralizes Omicron Subvariants BA.1, BA.2, BA.2.12.1, BA.3, and BA.4/BA.5 for Treatment of Coronavirus Disease 2019

Awasthi, M., Golding, H., & Khurana, S. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac642 · Cited by 13

Immune Correlates Analysis of a Single Ad26.COV2.S Dose in the ENSEMBLE COVID-19 Vaccine Efficacy Clinical TrialPreprint

Fong, Y., McDermott, A. B., Benkeser, D. C., Roels, S., Stieh, D. J., Vandebosch, A., Gars, M. L., Roey, G. A. V., Houchens, C. R., Martins, K. A. O., et al. (2022) · medRxiv · doi:10.1101/2022.04.06.22272763 · Cited by 13

Correlates of protection, viral load trajectories and symptoms in BA.1, BA.1.1 and BA.2 breakthrough infections in triple vaccinated healthcare workersPreprint

Marking, U. W., Havervall, S., Greilert‐Norin, N., Bladh, O., Christ, W., Gordon, M., Ng, H., Blom, K. G., Phillipson, M., Mangsbo, S. M., et al. (2022) · medRxiv · doi:10.1101/2022.04.02.22273333 · Cited by 13

Antibody and T-Cell Subsets Analysis Unveils an Immune Profile Heterogeneity Mediating Long-term Responses in Individuals Vaccinated Against SARS-CoV-2

Agallou, M., Koutsoni, O. S., Michail, M., Zisimopoulou, P., Tsitsilonis, O., & Karagouni, E. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac421 · Cited by 12

Assay Harmonization Study To Measure Immune Response to SARS-CoV-2 Infection and Vaccines: a Serology Methods Study

Kemp, T. J., Hempel, H., Pan, Y., Roy, D., Cherry, J. D., Lowy, D. R., & Pinto, L. A. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.05353-22 · Cited by 12

Immunogenicity and safety of heterologous immunisation with Ad5-nCOV in healthy adults aged 60 years and older primed with an inactivated SARS-CoV-2 vaccine (CoronaVac): a phase 4, randomised, observer-blind, non-inferiority trial

Jin, P., Guo, X., Gou, J.-B., Hou, L., Song, Z., Zhu, T., Pan, H., Zhu, J., Shi, F., Du, P., et al. (2023) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2023.100829 · Cited by 12

Antibodies to S2 domain of SARS-CoV-2 spike protein in Moderna mRNA vaccinated subjects sustain antibody-dependent NK cell-mediated cell cytotoxicity against Omicron BA.1

Balinsky, C. A., Jiang, L., Jani, V., Cheng, Y., Zhang, Z., Belinskaya, T., Qiu, Q., Long, T. K., Schilling, M. A., Jenkins, S. A., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1266829 · Cited by 15

Neutralization of SARS-CoV-2 Omicron BQ.1, BQ.1.1 and XBB.1 variants following SARS-CoV-2 infection or vaccination in children

Bellusci, L., Grubbs, G., Sait, S., Yonker, L. M., Randolph, A. G., Novak, T., Kobayashi, T., Overcoming COVID−19 Investigators, & Khurana, S. (2023) · Nature Communications · doi:10.1038/s41467-023-43152-y · Cited by 12

Infection-mediated immune response in SARS-CoV-2 breakthrough infection and implications for next-generation COVID-19 vaccine development

Miyamoto, S., & Suzuki, T. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.01.088 · Cited by 13

Factors impacting antibody kinetics, including fever and vaccination intervals, in SARS-CoV-2-naïve adults receiving the first four mRNA COVID-19 vaccine doses

Matsuura, T., Fukushima, W., Nakagama, Y., Kido, Y., Kase, T., Kondo, K., Kaku, N., Matsumoto, K., Suita, A., Mukai, E., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-57931-0 · Cited by 12

mRNA Vaccines Against COVID-19 as Trailblazers for Other Human Infectious Diseases

Brandi, R., Paganelli, A., D’Amelio, R., Giuliani, P., Lista, F. R., Salemi, S., & Paganelli, R. (2024) · Vaccines · doi:10.3390/vaccines12121418 · Cited by 13

Longitudinal Analysis of Antibody Responses to the mRNA BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis: A 6-Month Follow-Up

Weigert, A. L. L., Bergman, M., Gonçalves, L. A., Godinho, I., Duarte, N., Abrantes, R., Borges, P., Brennand, A., Malheiro, V., Matoso, P., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.796676 · Cited by 13

Sustained Antibody-Dependent NK Cell Functions in Mild COVID-19 Outpatients During Convalescence

Fuentes‐Villalobos, F., Garrido, J. L. V., Medina, M. A., Zambrano, N., Ross, N., Bravo, F., Gaete-Argel, A., Oyarzún-Arrau, A., Amanat, F., Soto‐Rifo, R., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.796481 · Cited by 12

Neutralization of SARS-CoV-2 Omicron after vaccination of patients with myelodysplastic syndromes or acute myeloid leukemia

Bellusci, L., Grubbs, G., Srivastava, P., Nemeth, M. J., Griffiths, E. A., Golding, H., & Khurana, S. (2022) · Blood · doi:10.1182/blood.2022016087 · Cited by 12

Humoral immune response characterization of heterologous prime-boost vaccination with CoronaVac and BNT162b2

Rammauro, F., Carrión, F., Olivero‐Deibe, N., Fló, M., Ferreira, A., Pritsch, O., & Bianchi, S. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.07.023 · Cited by 14

Clinical Development of mRNA Vaccines: Challenges and Opportunities

August, A., Brito, L., Paris, R., & Zaks, T. Z. (2022) · Current topics in microbiology and immunology · doi:10.1007/82_2022_259 · Cited by 12

Monitoring of Both Humoral and Cellular Immunities Could Early Predict COVID-19 Vaccine Efficacy Against the Different SARS-CoV2 Variants

Vogrig, M., Berger, A.-E., Bourlet, T., Waeckel, L., Haccourt, A., Chanavat, A. H., Hupin, D., Roche, F., Botelho-Nevers, É., Pozzetto, B., et al. (2022) · Journal of Clinical Immunology · doi:10.1007/s10875-022-01354-x · Cited by 13

Neutralizing immunity against SARS-CoV-2 Omicron BA.1 by infection and vaccination

Duan, L., Jiang, W. G., Wang, Z.-Y., Lin, Y., Zhu, K.-L., Meng, Q.-C., Wang, B., Li, L., Wang, G., & Ma, M. (2022) · iScience · doi:10.1016/j.isci.2022.104886 · Cited by 12

The impact of maternal SARS‐CoV‐2 vaccination and first trimester infection on feto‐maternal immune responses

Juttukonda, L. J., Wachman, E. M., Boateng, J. O., Clarke, K., Snyder-Cappione, J. E., & Taglauer, E. S. (2022) · American Journal of Reproductive Immunology · doi:10.1111/aji.13625 · Cited by 12

Severe SARS-Cov2 pneumonia in vaccinated patients: a multicenter cohort study

Mirouse, A., Friol, A., Moreau, A., Jung, B., Jullien, E., Bureau, C., Djibré, M., de Prost, N., Zafrani, L., Argaud, L., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-29131-9 · Cited by 13

Cytotoxic T Cells Targeting Spike Glycoprotein Are Associated with Hybrid Immunity to SARS-CoV-2

Phan, J. M., Layton, E. D., Yu, K. K. Q., Aguilar, M. S., Golez, I., Franko, N., Logue, J. K., Rodda, L. B., Howard, C. A., Pepper, M., et al. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2200815 · Cited by 12

Efficient and flexible mediation analysis with time-varying mediators, treatments, and confounders

Diaz, I. M., Williams, N., & Rudolph, K. E. (2023) · Journal of Causal Inference · doi:10.1515/jci-2022-0077 · Cited by 12

T cell control of SARS-CoV-2: When, which, and where?

Diniz, M. O., Maini, M. K., & Swadling, L. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101828 · Cited by 12

Immunogenicity of a Three-Dose Primary Series of mRNA COVID-19 Vaccines in Patients With Lymphoid Malignancies

Sherman, A. C., Crombie, J. L., Cheng, C., Desjardins, M., Zhou, G., Ometoruwa, O., Rooks, R., Senussi, Y., McDonough, M. M., Guerrero, L. I., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac417 · Cited by 12

Antibody and T-Cell Responses 6 Months after Covid-19 mRNA-1273 Vaccination in Patients with Chronic Kidney Disease, on Dialysis, or Living with a Kidney TransplantPreprint

Sanders, J., Messchendorp, A. L., de Vries, R. D., Baan, C. C., van Baarle, D., van Binnendijk, R. S., Diavatopoulos, D. A., Geers, D., Schmitz, K. S., GeurtsvanKessel, C. H., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4070419 · Cited by 12

Rapidly identifying new coronavirus mutations of potential concern in the Omicron variant using an unsupervised learning strategy

Zhao, L. P., Lybrand, T. P., Gilbert, P. B., Payne, T. H., Pyo, C., Geraghty, D. E., & Jerome, K. R. (2022) · Scientific Reports · doi:10.1038/s41598-022-23342-2 · Cited by 13

Humoral Responses in the Omicron Era Following 3-Dose SARS-CoV-2 Vaccine Series in Kidney Transplant Recipients

McEvoy, C. M., Hu, Q., Abe, K. T., Yau, K., Oliver, M. J., Levin, A., Gingras, A., Hladunewich, M., & Yuen, D. A. (2022) · Transplantation Direct · doi:10.1097/txd.0000000000001401 · Cited by 12

Immunogenicity Against Wild-Type and Omicron SARS-CoV-2 After a Third Dose of Inactivated COVID-19 Vaccine in Healthy Adolescents

Leung, D., Cohen, C. A., Mu, X., Duque, J. S. R., Cheng, S. M. S., Wang, X., Wang, M., Zhang, W., Zhang, Y., Tam, I. Y. S., et al. (2022) · Frontiers in Immunology · doi:10.2139/ssrn.4115862 · Cited by 11

Broad-spectrum vaccine via combined immunization routes triggers potent immunity to SARS-CoV-2 and its variants

Xing, M., Wang, Y., Wang, X., Liu, J., Dai, W., Hu, G., He, F., Zhao, Q., Li, Y., Sun, L., et al. (2023) · Journal of Virology · doi:10.1128/jvi.00724-23 · Cited by 12

Broad immunogenicity to prior SARS-CoV-2 strains and JN.1 variant elicited by XBB.1.5 vaccination in nursing home residents

Abul, Y., Nugent, C., Vishnepolskiy, I., Wallace, T., Dickerson, E., Holland, L., Esparza, I., Winkis, M., Wali, K. T., Chan, P. A., et al. (2024) · GeroScience · doi:10.1007/s11357-024-01346-2 · Cited by 10

A protein vaccine of RBD integrated with immune evasion mutation shows broad protection against SARS-CoV-2

An, R., Yang, H., Tang, C., Li, Q., Huang, Q. M., Wang, H., Wang, J., Zhou, Y., Yang, Y. K., Chen, H., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02007-8 · Cited by 11

Comparative study of neutralizing antibodies titers in response to different types of COVID-19 vaccines among a group of egyptian healthcare workers

Maher, S., assaly, N. M. E., Aly, D. M., Atta, S. A., Fteah, A. M., Badawi, H., Zahran, M. Y., & Kamel, M. M. (2024) · Virology Journal · doi:10.1186/s12985-024-02546-0 · Cited by 11

Advanced Detection of SARS-CoV-2 and Omicron Variants via MXene-Graphene Hybrid Biosensors Utilizing Nucleic Acid Probes

Li, J., Zhang, Y., Wei, C., Li, Y., Peng, Z., Chuang, H.-Y., Pearce, L., Boon, A. C. M., Huang, Y., Kim, D., et al. (2024) · ACS Applied Nano Materials · doi:10.1021/acsanm.4c05198 · Cited by 11

Vaccine-induced T cell responses correlate with reduced risk of severe COVID-19 in a placebo-controlled efficacy trial

Hertoghs, N., Roels, S., Brückner, M., SADOFF, J. C., Banbury, B. L., Akers, N. K., Howie, B., Robins, H. S., Roey, G. A. V., Tolboom, J. T. B. M., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105809 · Cited by 15

Serologic response to a third dose of an mRNA-based SARS-CoV-2 vaccine in lung transplant recipients

Hoffman, T. W., Meek, B., Rijkers, G. T., & van Kessel, D. A. (2022) · Transplant Immunology · doi:10.1016/j.trim.2022.101599 · Cited by 13

Effectiveness, safety, and immunogenicity of half dose ChAdOx1 nCoV-19 COVID-19 Vaccine: Viana project

Valim, V., Martins‐Filho, O. A., Gouvea, M. D. P. G., Camacho, L. A. B., Villela, D. A. M., de Lima, S. M. B., Azevedo, A. D. S., Neto, L. F. D. S. P., Domingues, C. M. A. S., de Medeiros, N. F., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.966416 · Cited by 11

Nanovaccines to combat virus‐related diseases

Wu, F., Qin, M., Wang, H., & Sun, X. (2022) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1857 · Cited by 11

Approaching COVID‐19 with epidemiological genomic surveillance and the sustainability of biodiversity informatics in Africa

Aborode, A. T., Huang, H. Y. R., Awuah, W. A., Mehta, A., Kalmanovich, J. B., Abdul‐Rahman, T., Sikora, V., & Awaji, A. A. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28308 · Cited by 10

Determinants of Anti-S Immune Response at 9 Months after COVID-19 Vaccination in a Multicentric European Cohort of Healthcare Workers—ORCHESTRA Project

Collatuzzo, G., Lodi, V., Feola, D., Palma, G. D., Sansone, E., Sala, E., Janke, C., Castelletti, N., Porru, S., Spiteri, G., et al. (2022) · Viruses · doi:10.3390/v14122657 · Cited by 11

Monitoring Temporal Changes in SARS-CoV-2 Spike Antibody Levels and Variant-Specific Risk for Infection, Dominican Republic, March 2021–August 2022

Nilles, E. J., Aubin, M. D. S., Dumas, D., Duke, W., Etienne, M. C., Abdalla, G., Jarolím, P., Oasan, T., Garnier, S., Iihoshi, N., et al. (2023) · Emerging infectious diseases · doi:10.3201/eid2904.221628 · Cited by 15

Challenges and Recent Advancements in COVID-19 Vaccines

Wang, S.-C., Rai, C.-I., & Chen, Y. (2023) · Microorganisms · doi:10.3390/microorganisms11030787 · Cited by 11

COVID-19 vaccine antibody responses in community-dwelling adults to 48 weeks post primary vaccine series

Walmsley, S. L., Szadkowski, L., Wouters, B. G., Clarke, R., Colwill, K., Rochon, P. A., Brudno, M., Ravindran, R., Raboud, J., McGeer, A., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106506 · Cited by 12

Coronavac inactivated vaccine triggers durable, cross-reactive Fc-mediated phagocytosis activities

Wang, L., Li, C., Li, W., Zhao, L., Zhao, T., Chen, L., Li, M., Fan, J., Li, J., Wu, C., et al. (2023) · Emerging Microbes & Infections · doi:10.1080/22221751.2023.2225640 · Cited by 11

Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial

Benkeser, D. C., Montefiori, D. C., McDermott, A. B., Fong, Y., Janes, H., Deng, W., Zhou, H., Houchens, C. R., Martins, K. A. O., Jayashankar, L., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.ade9078 · Cited by 44

Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial

Fong, Y., Huang, Y., Benkeser, D. C., Carpp, L. N., Áñez, G., Woo, W., McGarry, A., Dunkle, L. M., Cho, I., Houchens, C. R., et al. (2023) · Nature Communications · doi:10.1038/s41467-022-35768-3 · Cited by 101

Stochastic Interventional Vaccine Efficacy and Principal Surrogate Analyses of Antibody Markers as Correlates of Protection against Symptomatic COVID-19 in the COVE mRNA-1273 Trial

Huang, Y., Hejazi, N. S., Blette, B. S., Carpp, L. N., Benkeser, D. C., Montefiori, D. C., McDermott, A. B., Fong, Y., Janes, H., Deng, W., et al. (2023) · Viruses · doi:10.3390/v15102029 · Cited by 15

Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 COVE TrialPreprint

Sahly, H. M. E., Baden, L. R., Essink, B. J., Montefiori, D. C., McDermont, A., Rupp, R. E., Lewis, M., Swaminathan, S., Griffin, C., Fragoso, V. G., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3988003 · Cited by 2

Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine

Ma, C., Feng, J., Wahid, R., Chalkias, S., Edwards, D., Girard, B., Das, R., Zhou, H., & Zheng, L. (2026) · Figshare · doi:10.6084/m9.figshare.32531162